FILTER
FILTERED INTERVIEW RESULTS
Nick Grasman
LEAD MARKET MANAGER, DOW PHARMA SOLUTIONS, THE DOW CHEMICAL COMPANY
Dow Pharma Solutions develops functional excipients and APIs that enable improved pharmaceutical delivery and enhanced solubility.
Jay Dong
GENERAL MANAGER and GLOBAL VP, CST CHINA
CST is expanding its footprint across China where R&D and innovation spending is on the rise.
Mickey Kertesz
FOUNDER & CEO, KARIUS
The Karius test harnesses next-generation sequencing to detect fragments of cell-free DNA from bacteria, viruses, fungi and protozoa that may be circulating in a patient’s bloodstream.
William Hait
GLOBAL HEAD, JOHNSON & JOHNSON GLOBAL EXTERNAL INNOVATION
Johnson & Johnson invested US$10 billion in research and development in 2017 both internally and externally.
Jonathan Zhu
PARTNER PRACTICE LEADER, CHINA LIFE SCIENCE & GOVERNMENT AFFAIRS, HEIDRICK & STRUGGLES
H&S is one of the top five recruiting firms globally and is expanding its services in China’s rapidly growing life science sector.
Dr. Wu Xiaobing
COUNTRY MANAGER, PFIZER CHINA & REGIONAL PRESIDENT, PFIZER ESSENTIAL HEALTH GREATER CHINA
Pfizer speaks to GBR about its operations in China.
Joseph Colleluori
SENIOR VICE PRESIDENT CORPORATE DEVELOPMENT, LONZA GROUP
Headquartered in Switzerland and traded on the Swiss stock exchange, Lonza is a leading supplier to the pharma and biotech industries.
Ningling Wang
MANAGING PARTNER, FINNEGAN
Finnegan in Shanghai helps Chinese companies protect and enforce their IP in the US and also helps foreign clients with patent litigation in China.
Greg Scott
CEO, CHINABIO CONSULTING
ChinaBio morphed from being an angel investor in China to becoming a consultant for foreign compa-nies looking to enter the Chinese life science space.
Brian Frenzel
PRESIDENT AND CEO, TOSK, INC.
Tosk, Inc. is a small molecule, oncology drug discovery and development company.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2024 - Digital Interactive
"Cautious optimism. These two words best describe the state of mind of life sciences executives as we enter the second half of 2024. "
"Cautious optimism. These two words best describe the state of mind of life sciences executives as we enter the second half of 2024. "
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
